The effects of tocilizumab in cancer disease are similar to those of RA, with patients receiving tocilizumab experiencing functional IL-6R blockade, increased serum IL-6 and soluble IL-6R levels, decreased levels of phosphorylated STAT3, and more active T-cell function in vivo, secreting more interferon-gamma and tumor necrosis factor-alpha [96]. Here, IL6 is linked to cancer.